Horizon Kinetics Asset Management LLC Has $524,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Horizon Kinetics Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 735 shares of the biopharmaceutical company’s stock after acquiring an additional 29 shares during the quarter. Horizon Kinetics Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $524,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in REGN. Amundi lifted its position in shares of Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Proficio Capital Partners LLC raised its holdings in Regeneron Pharmaceuticals by 92,865.3% in the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after acquiring an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $127,489,000. KBC Group NV raised its holdings in Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after acquiring an additional 102,198 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $65,180,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of REGN opened at $678.42 on Tuesday. The firm has a market capitalization of $74.17 billion, a price-to-earnings ratio of 17.72, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business’s fifty day moving average price is $694.15 and its two-hundred day moving average price is $827.65. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $11.86 EPS. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on REGN shares. Robert W. Baird cut their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a report on Wednesday, February 5th. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a report on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Finally, TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.